Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C1680
http://purl.obolibrary.org/obo/NCIT_C1680
|
|---|---|
| Preferred Name | Iboctadekin |
| Definitions |
A recombinant therapeutic agent which is chemically identical to or similar to the endogenous cytokine interleukin-18 (IL-18). Produced primarily by macrophages, IL-18 induces the production of interferon-gamma (IFN-gamma), and enhances the activity of natural killer (NK) and cytotoxic T lymphocytes (CTL). As a potential immunotherapeutic agent, iboctadekin displays antitumor effects in vitro and in animal models. (NCI04)
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | A recombinant therapeutic agent which is chemically identical to or similar to the endogenous cytokine interleukin-18 (IL-18). Produced primarily by macrophages, IL-18 induces the production of interferon-gamma (IFN-gamma), and enhances the activity of natural killer (NK) and cytotoxic T lymphocytes (CTL). As a potential immunotherapeutic agent, iboctadekin displays antitumor effects in vitro and in animal models. (NCI04) |
|---|---|
| prefLabel | Iboctadekin
|
| label | Iboctadekin
|
| PDQ_Closed_Trial_Search_ID | 386168
|
| code | C1680
|
| prefixIRI | NCIT:C1680
|
| in_subset |
See more
See less
|
| Display_Name | Iboctadekin
|
| Preferred_Name | Iboctadekin
|
| FDA_UNII_Code | X08H9UZ7TO
|
| Contributing_Source |
CTRP
FDA
|
| Maps_To |
Recombinant Interleukin-18
Iboctadekin
|
| CAS_Registry | 479198-61-3
|
| NCI_Drug_Dictionary_ID | 386168
|
| Legacy Concept Name | Therapeutic_Interleukin-18
|
| type | |
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 386168
|
| Semantic_Type |
Amino Acid, Peptide, or Protein
Pharmacologic Substance
|
| UMLS_CUI | C1527127
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |